Page 21 - Read Online

Murray Primary circulating prostate cells

17. Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Change in 35. Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Significance of MMP-2
prostate cancer grade over time in men followed expectantly for stage expression in prostate cancer: an immunohistochemical study. Cancer
T1c disease. J Urol 2008;179:901-4. Res 2003;63:8511-5.
18. Berglund RK, Materson TA, Vora KC, Eggener SE, Eastham JA, 36. Murray NP, Reyes E, Orellana N, Fuentealba C, Dueñas R, Jacob O.
Guillonneau BD. Pathological upgrading and up staging with Expression of P504S and matrix metalloproteinase-2 in circulating
immediate repeat biopsy in patients eligible for active surveillance. J prostate cells disseminated as a result of transrectal ultrasound guided
Urol 2008;180:1964-7. biopsy as determined by immunocytochemistry: clinical implications.
19. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh Arch Esp Urol 2015;68:474-81.
PC. The natural history of progression after PSA elevation following 37. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V,
radical prostatectomy. JAMA 1999;281:1591-7. Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL. Detection
20. Amling CL, Blute ML, Bergstrahl EJ, Seay TM, Slezak J, Zincke and characterization of invasive circulating tumor cells derived from
H. Long term hazard of progression after radical prostatectomy for men with metastatic castration-resistant prostate cancer. Int J Cancer
clinically localized prostate cancer: continued risk of biochemical 2014;134:2284-93.
failure after 5 years. J Urol 2000;164:101-5. 38. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL,
21. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco
SG, Gomella LG. Detection of hematogenous micrometastasis in MA. Circulating tumor cells from patients with advanced prostate and
patients with prostate cancer. Cancer 1992;52:6110-2. breast cancer display both epithelial and mesenchymal markers. Mol
22. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical Cancer Res 2011;9:997-1007.
implications of circulating tumor cells. EMBO Mol Med 2015;7:1-11. 39. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach
23. Murray NP, Reyes E, Orellana N, Fuentealba C, Dueñas R, Jacob O. RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME,
Expression of P504S and matrix metalloproteinase-2 in circulating Thompson IM, Huang TH. Single-cell analysis of circulating tumor
prostate cells disseminated as a result of transrectal ultrasound guided cells identifies cumulative expression patterns of EMT-related genes
biopsy as determined by immunocytochemistry: clinical implications. in metastatic prostate cancer. Prostate 2013;73:813-26.
ArchEsp Urol 2015;68:474-81. 40. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega
24. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization
Science 2011;331:1559-64. requires the repression of the epithelial-mesenchymal transition
25. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. inducer Prrx1. Cancer Cell 2012;22:709-24.
Aberrant expression of E-cadherin and beta-catenin in human prostate 41. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal
cancer. Urol Onc 2005;23:402-6. regulation of epithelial-mesenchymal transition is essential for
26. Umbas R, Schalken JA, AaldersTW, Carter BS, Karthaus HF, squamous cell carcinoma metastasis. Cancer Cell 2012;22:725-36.
Schaafsma HE, Debruyne FM, Isaacs WB. Expression of the cellular 42. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, Hu GF.
adhesion molecule E-cadherin is reduced or absent in high-grade Epithelial-mesenchymal transition induced by growth suppressor
prostate cancer. Cancer Res 1992;52:5104-9. p12CDK2-AP1 promotes tumor cell local invasion but suppresses
27. Pontes J Jr, Srougi M, Borra PM, Dall’ Oglio MF, Ribeiro-Filho LA, distant colony growth. Cancer Res 2008;68:10377-86.
Leite KR. E-cadherin and beta-catenin loss of expression related 43. Celia-Terrassa T, Meca-Cortes O, Mateo F. Martínez de Paz A, Rubio
to bone metastasis in prostate cancer. Appl Immunohistochem Mol N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M,
Morphol 2010;18:179-84. Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R,
28. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang
Co-ordinated changes in expression of cell adhesion molecules in Y, Blanco J, Fernández PL, Thomson TM. Epithelial-mesenchymal
prostate cancer. Eur J Cancer 1997;33:263-71. transition can suppress major attributes of human epithelial tumor-
29. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, initiating cells. J Clin Invest 2012;122:1849-68.
Nicolò G, Boccardo F, Galli S, Patrone E, Balbi C. Changes in the 44. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells
expression of cytokeratins and nuclear matrix proteins are correlated within a malignant tumor. Science 1977;197:893-5.
with the level of differentiation in human prostate cancer. J Cell 45. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A,
Biochem 2000;79:471-85. Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz
30. Chambers AF, Matrisian LM. Changing views of the role of matrix T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K,
metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70. Weichert W, Trumpp A. Identification of a population of blood
31. Stearns ME, Stearns M. Immunohistochemical studies of activated circulating tumor cells from breast cancer patients that initiates
matrix metalioproteinase-2 (MMP-2a) expression in human prostate metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
cancer. Oncol Res 1996;8:63-7. 46. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Plasticity of
32. Wood DP, Banerjee M. Presence of circulating prostate cells in disseminating cancer cells in patients with epithelial malignancies.
the bone marrow of patients undergoing radical prostatectomy is Cancer Metastasis Rev 2012;31:673-87.
predictive of disease-free survival. J Clin Oncol 1997;15:3451-7. 47. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal
33. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, plasticity in cancer. Nat Med 2013;19:1438-49.
Pettaway CA. Relative expression of type IV collagenase, E-cadherin, 48. Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S,
and vascular endothelial growth factor/vascular permeability Mischinger J, Kühs U, Gerber V, Fetisch J, Schilling D, Hauch S,
factor in prostatectomy specimens distinguishes organ-confined Stenzl A, Schwentner C. Preliminary experience on the use of the
from pathologically advanced prostate cancers. Clin Cancer Res Adnatest(R) system for detection of circulating tumor cells in prostate
2000;6:2295-308. cancer patients. Anticancer Res 2012;32:3507-13.
34. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury 49. Alix-Panabières C, Pantel K. Challenges in circulating tumor cell
BV. rognostic significance of matrix metalloproteinase 2 and tissue research. Nat Rev Cancer 2014;14:623-31.
inhibitor of metalloproteinase 2 expression in prostate cancer. Mod 50. Trzpis M, McLaughhlin PMJ, de Leij LMFH, Harmsen MC. Epithelial
Pathol 2003;16:198-205. cell adhesion molecule: more than a carcinoma marker and adhesion
460 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ December 16, 2016